Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - venetoclaxum - comprimés pelliculés - venetoclaxum 100 mg, copovidonum k 28, polysorbatum 80, silica colloidalis anhydrica, calcii phosphas, natrii stearylis fumaras corresp. natrium 0.31 mg, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, e 172 (flavum), pro compresso obducto. - chronisch lymphatische leukämie (cll), akute myeloische leukämie (aml) - synthetika

Canada - français - Health Canada

eisai limited - mésylate d'Éribuline - solution - 0.5mg - mésylate d'Éribuline 0.5mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agents antinéoplasiques - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Canada - français - Health Canada

celgene inc - ÉnasidÉnib (mesylate d'ÉnasidÉnib) - comprimé - 50mg - ÉnasidÉnib (mesylate d'ÉnasidÉnib) 50mg - antineoplastic agents

Canada - français - Health Canada

celgene inc - ÉnasidÉnib (mesylate d'ÉnasidÉnib) - comprimé - 100mg - ÉnasidÉnib (mesylate d'ÉnasidÉnib) 100mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leucémie, myéloïde, aiguë - agents antinéoplasiques - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Union européenne - français - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - agents antinéoplasiques - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Union européenne - français - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - le myélome multiple - agents antinéoplasiques - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Canada - français - Health Canada

jazz pharmaceuticals ireland limited - lurbinectédine - poudre - 4mg - lurbinectédine 4mg - antineoplastic agents

Canada - français - Health Canada

forus therapeutics inc. - sélinexor - comprimé - 20mg - sélinexor 20mg